Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Oropharyngeal Neoplasms 4Head and Neck Neoplasms 3Rectal Neoplasms 2Pathologic Complete Response 2Lung Neoplasms 2Glioblastoma 2Uterine Cervical Neoplasms 1Tobacco Use Disorder 1Thymoma 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Smoking Cessation 1Smoking 1Sinonasal undifferentiated carcinoma 1Sinonasal Squamous Cell Carcinoma 1Rectal Malignant Neoplasms 1Radiation Injuries 1Postoperative Complications 1Paranasal Sinus Neoplasms 1Papillomavirus Infections 1Pancreatic Neoplasms 1Mouth Neoplasms 1Low Anterior Resection Syndrome 1Laryngeal Neoplasms 1Infiltrating Bladder Urothelial Carcinoma 1HPV-Related Squamous Cell Carcinoma 1Fatigue 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

cemiplimab 1Taxes 1Surgical Procedures, Operative 1Specimen Handling 1Radiotherapy 1Radiation 1Platinum 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Cisplatin 1Chemoradiotherapy 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sinonasal Squamous Cell Carcinoma × Chemoradiotherapy × 90 days × Clear all
NCT07281417 2026-05-22

Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

National Cancer Institute (NCI)

Phase 2 Recruiting
108 enrolled

Sinonasal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡